FDA has declined Humanigen's Emergency Use Authorization (EUA) Request for Lenzilumab in Hospitalized COVID-19 PatientsBusiness Wire • 09/09/21
KaloBios Pharmaceuticals Inc. (HGEN) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/12/21
Humanigen's COVID-19 Candidate Shows 2.5 Fold Increase In Survival Without VentilationBenzinga • 08/04/21
Lenzilumab Treatment May Provide Enhanced Likelihood of Survival Without Ventilation in Hospitalized Black and African-American COVID-19 PatientsBusiness Wire • 08/04/21
NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19Business Wire • 07/30/21
Humanigen's Partner in South Korea Receives Ministry of Food and Drug Safety (MFDS) Approval to Conduct Phase 1 Study of LenzilumabBusiness Wire • 07/22/21
Is the Options Market Predicting a Spike in Humanigen (HGEN) Stock?Zacks Investment Research • 07/12/21
UK's MHRA accepts Humanigen's submission of Lenzilumab for Marketing Authorization in COVID-19 for expedited rolling reviewBusiness Wire • 07/09/21
Humanigen Initiates Submission for Lenzilumab Marketing Authorization in COVID-19, to the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA)Business Wire • 06/14/21
Humanigen Announces Ken Trbovich Appointed as Senior Vice President, Investor RelationsBusiness Wire • 06/07/21
Humanigen Submits Application to FDA for Emergency Use Authorization for Lenzilumab in COVID-19Business Wire • 05/28/21
GM-CSF Gene-Edited CAR-T Data to be Presented at International Society for Cell & Gene Therapy Annual Meeting 2021Business Wire • 05/26/21
Humanigen and Chime Biologics Enter Into Manufacturing Agreement for COVID-19 Therapeutic Candidate LenzilumabBusiness Wire • 05/17/21